FDA allows SMSbiotech inhaled stem cell therapy to enter U.S. COPD trial
SMSbiotech has received an FDA “study may proceed” notification for a Phase 1b U.S. trial of nebulized allogeneic SMS Cells in COPD, with first dosing targeted for the fourth quarter.